Pharma: Other News To Note
• CSL Behring Ltd., of King of Prussia, Pa., said the FDA accepted for review its biologics license application for a human 4-factor prothrombin complex concentrate for the urgent reversal of vitamin K-antagonist therapy (i.e. warfarin) in patients with acute major bleeding.
